Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Trial of LBP-EC01 to Target Escherichia coli (E. coli) Bacteria Causing Recurrent Urinary Tract Infections (UTIs)

Next Previous
Trial Profile

A Phase 3 Trial of LBP-EC01 to Target Escherichia coli (E. coli) Bacteria Causing Recurrent Urinary Tract Infections (UTIs)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LBP EC01 (Primary)
  • Indications Escherichia coli infections; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Locus Biosciences

Most Recent Events

  • 12 Aug 2024 According to a Locus Biosciences media release, BARDA will provide up to $93 million to Locus as part of a $152 million program to support Phase 2 and Phase 3 clinical trials and other activities required to seek marketing approval from the U.S. Food and Drug Administration (FDA) for LBP-EC01.
  • 18 May 2022 According to a Locus Biosciences media release, this phase II/III trial is anticipated to initiate in mid 2022.
  • 05 Oct 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top